1T3.MU Stock Analysis
1T
Uncovered
Syndax Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2016-03-03. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The firm is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.